On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...

In response, scientists have spent years searching for a safer alternative. That’s where crinecerfont, the active ingredient in Crenessity, comes in. Before the first prescription could be ...

Speiser was a consultant to Neurocrine Biosciences and was a principal investigator in the pediatric trial for crinecerfont (Crenessity). The insights shared here represent her knowledge as a med ...

The company’s Crinecerfont recently obtained Breakthrough Therapy designation for congenital adrenal hyperplasia (CAH).

Its flagship product, Ingrezza (valbenazine), is for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. The company’s Crinecerfont recently obtained Breakthrough ...

The company’s Crinecerfont recently obtained Breakthrough Therapy designation for congenital adrenal hyperplasia (CAH). In addition to Ingrezza, Neurocrine’s diverse portfolio contains other ...

The company’s Crinecerfont recently obtained Breakthrough Therapy designation for congenital adrenal hyperplasia (CAH). In addition to Ingrezza, Neurocrine’s diverse portfolio contains other ...

Neurocrine's pipeline represents a critical component of its future growth strategy. The company is awaiting FDA decisions on crinecerfont for congenital adrenal hyperplasia (CAH), with PDUFA dates ...

The company is awaiting FDA decisions on crinecerfont for congenital adrenal hyperplasia (CAH), with PDUFA dates set for late December 2024. Analysts project potential peak sales for crinecerfont ...

However, data regarding ... Crinecerfont results in a greater decrease from baseline in the mean daily glucocorticoid dose among patients with congenital adrenal hyperplasia (CAH), according to a ...